Patients have been aware in recent years of steep increases in the cost of prescription drugs which they require. Public attention to this issue escalated last year after the cost of Daraprim, a drug used to treat toxoplasmosis, a parasitic disease posing a threat to patients with HIV/AIDS and other immune disorders, was raised from $13.75 to $750 per capsule.
Despite a public outcry, that is the price quoted today at GoodRx.com
Turing Pharmaceuticals, a small, privately held company, bought the rights to Daraprim early last year from Imax Laboratories for $55 million. The market for the drug was small with sales of 9 million per year. Daraprim, however, was critical to the survival of hundreds of Americans.
Congress responded to the price hike of Daraprim with hearings in which which Turing’s CEO, Martin Shkreli, repeatedly invoked his Fifth Amendment rights in his testimony. He subsequently resigned because of unrelated charges of securities fraud. Turing countered adverse publicity by promising that the company would assure access to Daraprim by anyone who needed it, regardless of ability to pay.
Other steep price hikes have garnered less publicity despite affecting many thousands of patients.
